Inclusion Criteria

Patients must have:

• HIV positivity.
• CD4 count >= 500 cells/mm3.
• No history of AIDS-defining opportunistic infection, or malignancy other than mucocutaneous Kaposi's sarcoma.

Concurrent Medication: Required:

• Concurrent FDA-approved antiretroviral therapy (AZT, ddI, ddC, d4T).

Prior Medication: Required:

• FDA-approved antiretroviral therapy for at least 6 weeks prior to study entry.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

• Significant cardiac, pulmonary, thyroid, renal, or CNS disease.

Prior Medication:

Excluded:

• Prior IL-2.
• Systemic corticosteroids, chemotherapy, or experimental therapy within 4 weeks prior to study entry.